Dominas Christine, Deans Kyle, Packard Robert, Jonas Oliver
Brigham and Women's Hospital, Boston, MA, USA.
Dana-Farber Cancer Institute, Boston, MA, USA.
MethodsX. 2021 May 13;8:101382. doi: 10.1016/j.mex.2021.101382. eCollection 2021.
Implantable drug-delivery microdevices are a key diagnostic and therapeutic tool in medicine with increasing applications. Preparation of such combination drug-delivery devices for human studies requires the development of methods to ensure sterility, safety and integrity on both the device and drug side. Despite growing applications for these technologies, there has been a lack of clear methodology regarding sterilization and preparation to meet strict guidelines set forth by the Food and Drug Administration (FDA). Our laboratory developed a set of widely applicable and straightforward procedures to prepare drug-device combination products for clinical use that consistently achieve the high-quality standards provided by the FDA. This includes several newly developed methods for preparation of the implant including endotoxin removal, appropriate sterilization of raw materials, formulation of novel pharmaceutical agents, and loading of agents into drug delivery reservoirs. We also discuss protocols and methods developed with FDA to meet regulatory guidelines to ensure continual sterility and endotoxin testing, as well as longer-term stability testing of drugs and biologic agents.•Endotoxin removal and sterilization of raw materials for clinical use.•Formulation and device loading of novel pharmaceutical agents.•Continued testing of pharmaceutical agents and devices to meet regulatory guidelines.
可植入式药物递送微型装置是医学领域中一种关键的诊断和治疗工具,其应用日益广泛。为人体研究制备此类联合药物递送装置需要开发方法,以确保装置和药物两方面的无菌性、安全性和完整性。尽管这些技术的应用不断增加,但在满足美国食品药品监督管理局(FDA)制定的严格指南方面,缺乏关于灭菌和制备的明确方法。我们实验室开发了一套广泛适用且简单直接的程序,用于制备临床使用的药物-装置组合产品,始终达到FDA规定的高质量标准。这包括几种新开发的植入物制备方法,包括内毒素去除、原材料的适当灭菌、新型药剂的配制以及将药剂加载到药物递送储库中。我们还讨论了与FDA共同制定的方案和方法,以满足监管指南,确保持续的无菌性和内毒素检测,以及药物和生物制剂的长期稳定性测试。
•临床使用原材料的内毒素去除和灭菌。
•新型药剂的配制和装置加载。
•持续检测药剂和装置以满足监管指南。